NCT06890273 (DUOLife) is a clinical trial in Endometrial Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT06890273?

NCT06890273 is sponsored by AstraZeneca.

What condition does NCT06890273 study?

NCT06890273 studies Endometrial Cancer.

Is NCT06890273 still recruiting?

NCT06890273 is currently recruiting now. Last updated 18 February 2026.

Last reviewed 2026-02-18 · How we verify

NCT06890273: DUOLife

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Recruiting now Last updated 18 February 2026

What this trial tests

trial in Endometrial Cancer in 150 participants. Currently enrolling.

Timeline

20 May 2025

Primary endpoint
30 September 2028

30 September 2028

Quick facts

Lead sponsor	AstraZeneca
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	150
Start date	20 May 2025
Primary completion	30 September 2028
Estimated completion	30 September 2028
Sites	33 locations across Germany

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical and patient-reported outcome (PRO) data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy.
Liu Q, Zhang C, Gao Y, Feng D, et al · · 2025 · PMID 41402978 · DOI 10.1186/s12957-025-04101-9

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06890273 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 18 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06890273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing